文献速递糖尿病骨质疏松与钙磷/甲状旁腺

糖尿病患者骨脆性的生化标志物

Biochemical Markers of Bone Fragility in Patients with Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-05-08

国际骨质疏松基金会与欧洲钙化组织学会专家组综述成人糖尿病中骨与糖代谢相关生化标志物与骨脆性及骨折风险的关系。骨吸收与骨形成标志物在糖尿病中偏低且对骨折预测能力差,抗骨质疏松药物对骨转换标志物的改变与非糖尿病者相似并伴骨折风险类似下降。目前仅糖化血红蛋白A1c(HbA1c)似能可靠估计骨折风险,骨转换标志物可用于监测抗骨质疏松治疗效应。

要点

  • 骨吸收与骨形成标志物在糖尿病中偏低,对骨折风险预测能力差。
  • 抗骨质疏松药物对糖尿病患者骨转换标志物的改变与非糖尿病者相似,骨折风险下降也相似。
  • 目前仅HbA1c水平似能可靠估计糖尿病患者的骨折风险。

核心结论

  • 多种与骨和/或糖代谢相关的生化标志物及激素水平与糖尿病患者的骨骼参数相关。
  • 目前仅HbA1c水平似能提供可靠的骨折风险估计,而骨转换标志物可用于监测抗骨质疏松治疗的效果。

研究设计与样本

  • 国际骨质疏松基金会与欧洲钙化组织学会的专家组对成人中生化标志物、糖尿病、糖尿病治疗与骨骼相关文献进行综述。

主要发现

  • 骨吸收和骨形成标志物在糖尿病中偏低,且对骨折风险的预测能力差。
  • 骨质疏松药物在糖尿病患者中似乎对骨转换标志物的改变与非糖尿病者相似,骨折风险下降也相似。
  • 骨细胞相关标志物(如硬骨素)、糖化血红蛋白A1c(HbA1c)与晚期糖基化终产物、炎症标志物、脂肪因子以及胰岛素样生长因子-1和钙调节激素等多种标志物与糖尿病中的骨密度和/或骨折风险相关。

临床怎么用

  • 目前仅HbA1c水平似能可靠估计糖尿病患者的骨折风险。
  • 骨转换标志物可用于监测抗骨质疏松治疗的效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The risk of fragility fractures is increased in both type 1 and type 2 diabetes. Numerous biochemical markers reflecting bone and/or glucose metabolism have been evaluated in this context. OBJECTIVE: This review summarizes current data on biochemical markers in relation to bone fragility and fracture risk in diabetes. METHODS: A group of experts from the International Osteoporosis Foundation and European Calcified Tissue Society reviewed the literature focusing on biochemical markers, diabetes, diabetes treatments, and bone in adults. RESULTS: Although bone resorption and bone formation markers are low and poorly predictive of fracture risk in diabetes, osteoporosis drugs seem to change bone turnover markers (BTMs) in diabetics similarly to nondiabetics, with similar reductions in fracture risk. Several other biochemical markers related to bone and glucose metabolism have been correlated with bone mineral density and/or fracture risk in diabetes, including osteocyte-related markers such as sclerostin, glycated hemoglobin A1c (HbA1c) and advanced glycation end products, inflammatory markers, and adipokines, as well as insulin-like growth factor-1 and calciotropic hormones. CONCLUSION: Several biochemical markers and hormonal levels related to bone and/or glucose metabolism have been associated with skeletal parameters in diabetes. Currently, only HbA1c levels seem to provide a reliable estimate of fracture risk, while BTMs could be used to monitor the effects of antiosteoporosis therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Meier C, Eastell R, Pierroz DD, et al. Biochemical Markers of Bone Fragility in Patients with Diabetes. J Clin Endocrinol Metab. 2023. PMID: 37155585. doi:10.1210/clinem/dgad255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。